Zobrazeno 1 - 10
of 504
pro vyhledávání: '"Fortunato, Morabito"'
Autor:
Lucia Mangone, Federica Mereu, Maurizio Zizzo, Andrea Morini, Magda Zanelli, Francesco Marinelli, Isabella Bisceglia, Maria Barbara Braghiroli, Fortunato Morabito, Antonino Neri, Massimiliano Fabozzi
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 2907-2917 (2024)
Enhanced Recovery After Surgery (ERAS) protocols have changed perioperative care, aiming to optimize patient outcomes. This study assesses ERAS implementation effects on postoperative complications, length of hospital stay (LOS), and mortality in col
Externí odkaz:
https://doaj.org/article/f2afcf96c24440d1b710a9546b75b034
Autor:
Lucia Mangone, Francesco Marinelli, Isabella Bisceglia, Angelina Filice, Maria Barbara Braghiroli, Francesca Roncaglia, Andrea Palicelli, Fortunato Morabito, Antonino Neri, Roberto Sabbatini, Cinzia Iotti, Carmine Pinto
Publikováno v:
Biology, Vol 13, Iss 7, p 499 (2024)
The COVID-19 pandemic has caused delays in cancer diagnoses and reductions in treatments. The aim of this work is to evaluate the impact of the pandemic on prostate cancer by evaluating whether there has been a shift towards more aggressive (Gleason)
Externí odkaz:
https://doaj.org/article/4b29f2c1aea74b41ab7fe97a66604e90
Autor:
Antonella Bruzzese, Ernesto Vigna, Dario Terzi, Sonia Greco, Enrica Antonia Martino, Valeria Vangeli, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Rosellina Morelli, Antonino Neri, Fortunato Morabito, Francesco Zinno, Antonio Mastroianni, Massimo Gentile
Publikováno v:
Hematology Reports, Vol 15, Iss 3, Pp 448-453 (2023)
Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening, rare acute thrombotic microangiopathy (TMA), caused by a severe ADAMTS13 deficiency. As the COVID-19 pandemic rapidly spread around the globe, much data about the pathogenic
Externí odkaz:
https://doaj.org/article/e19870b16e0f477ea522b353186a75d3
Autor:
Fortunato Morabito, Carlo Adornetto, Paola Monti, Adriana Amaro, Francesco Reggiani, Monica Colombo, Yissel Rodriguez-Aldana, Giovanni Tripepi, Graziella D’Arrigo, Claudia Vener, Federica Torricelli, Teresa Rossi, Antonino Neri, Manlio Ferrarini, Giovanna Cutrona, Massimo Gentile, Gianluigi Greco
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Analyzing gene expression profiles (GEP) through artificial intelligence provides meaningful insight into cancer disease. This study introduces DeepSHAP Autoencoder Filter for Genes Selection (DSAF-GS), a novel deep learning and explainable artificia
Externí odkaz:
https://doaj.org/article/e4e5174b1d3840d68699b7e42b5c9647
Autor:
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Enrica Antonia Martino, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Alessandra Pompa, Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Eleonora Ferretti, Giuseppe Bertuglia, Davide Nappi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to its approval for the treatmen
Externí odkaz:
https://doaj.org/article/73f1dbd9f0594c46b0da5f764f3377db
Autor:
Lucia Mangone, Domenico Penna, Francesco Marinelli, Francesca Roncaglia, Isabella Bisceglia, Francesco Merli, Alessia Ruffini, Barbara Gamberi, Alessia Tieghi, Riccardo Valli, Laura Albertazzi, Mauro Iori, Paolo Giorgi Rossi, Claudia Vener, Fortunato Morabito, Antonino Neri, Stefano Luminari
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundHematological malignancies (HMs) represent a heterogeneous group of diseases with diverse etiology, pathogenesis, and prognosis. HMs’ accurate registration by Cancer Registries (CRs) is hampered by the progressive de-hospitalization of pa
Externí odkaz:
https://doaj.org/article/725ed39a764949bf8bbc7bcfc8280cec
Autor:
Lucia Mangone, Francesco Marinelli, Isabella Bisceglia, Maria Barbara Braghiroli, Valentina Mastrofilippo, Annamaria Pezzarossi, Fortunato Morabito, Lorenzo Aguzzoli, Vincenzo Dario Mandato
Publikováno v:
Healthcare, Vol 12, Iss 1, p 64 (2023)
This study aimed to assess the impact of a multidisciplinary team (MDT) approach on outcomes with endometrial cancer (EC) patients, utilizing 2013–2020 data from the Reggio Emilia Cancer Registry. Recurrence rate, treatments, and outcome indicators
Externí odkaz:
https://doaj.org/article/3f34a3069772438b85604cc3fbc072d0
Autor:
Lucia Mangone, Francesco Marinelli, Isabella Bisceglia, Cristina Masini, Andrea Palicelli, Fortunato Morabito, Stefania Di Girolamo, Antonino Neri, Carmine Pinto
Publikováno v:
Biology, Vol 12, Iss 11, p 1409 (2023)
This study investigated the incidence, mortality, and 5-year survival rates of testicular cancers diagnosed in a northern Italian province, which were eventually associated with previous or subsequent extratesticular neoplasms. Cases from 1996 to 202
Externí odkaz:
https://doaj.org/article/15d7b666a26e4576a478e3bdd6aa7fbb
Autor:
Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio Pinto
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-10 (2021)
Abstract Background Overweight and obese patients with solid tumors receiving anti-programmed cell death-1 (PD-1)/PD-ligand-1(PD-L1) immune checkpoint inhibitors exhibit improved survival and higher risk of immune-related adverse events (irAEs) than
Externí odkaz:
https://doaj.org/article/f8e8de9a4961465ba54ef26969155fce
Autor:
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidom
Externí odkaz:
https://doaj.org/article/558f55d38b4c4a8a985194fbba17f62d